阿斯利康(LON：AZN)PT由德意志银行设定在GB 115...

Deutsche Bank Rese... set a £115 ($139.26) price target on AstraZeneca (LON:AZN – Get Rating) in a report issued on Tuesday, Borsen Zeitung reports.

Several other equities research analysts have also commented on AZN. Shore Capital reissued a buy rating on shares of AstraZeneca in a research note on Tuesday, June 28th. Barclays reissued an overweight rating and set a £120 ($145.31) price objective on shares of AstraZeneca in a research note on Monday, May 30th. JPMorgan Chase & Co. set a £120 ($145.31) price objective on shares of AstraZeneca in a research note on Monday, June 6th. Deutsche Bank Aktiengesellschaft reissued a buy rating and set a £115 ($139.26) price objective on shares of AstraZeneca in a research note on Wednesday, June 29th. Finally, The Goldman Sachs Group set a GBX 6,950 ($84.16) target price on shares of AstraZeneca in a research note on Friday, April 29th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, AstraZeneca presently has a consensus rating of Buy and an average target price of £105.46 ($127.70).

Shares of LON AZN opened at £108 ($130.78) on Tuesday. AstraZeneca has a 1 year low of GBX 8,029 ($97.23) and a 1 year high of £110.54 ($133.86). The company has a debt-to-equity ratio of 90.06, a current ratio of 1.00 and a quick ratio of 0.65. The company's 50-day moving average is £103.86 and its 200 day moving average is GBX 9,609.77. The stock has a market capitalization of £167.34 billion and a P/E ratio of -183.67.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

• Vera Bradley Stock Getting Cheap
• 3 Education Stocks to Enroll in This Summer
• The Institutions Get Comfortable With The Lovesac Company
• McDonald's Might Just Be The Best Recession Proof Stock
• Basset Furniture Quietly Proves Its Value

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.